Trevena Announces Pricing of Initial Public Offering of 9,250,000 Shares of Common Stock

Jan 31, 2014 6:30am EST

Trevena Announces Pricing of Initial Public Offering

Jan 30, 2014 5:34pm EST

Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of TRV027 for Acute Heart Failure

Jan 09, 2014 7:00am EST

Trevena Appoints Francois Nader, MD, to its Board of Directors

Jan 08, 2014 7:00am EST

First Clinical Experience of Trevena's lead CNS Biased Ligand, TRV130, Published in Journal of Clinical Pharmacology

Oct 15, 2013 8:00am EDT

Trevena Files Registration Statement for Proposed Initial Public Offering

Oct 10, 2013 7:00am EDT

Trevena Appoints Roberto Cuca as Senior Vice President & Chief Financial Officer

Sep 17, 2013 1:18pm EDT

Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study

Jul 30, 2013 7:00am EDT

Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.

Jul 17, 2013 7:00am EDT

Journal of Clinical Pharmacology Publishes First Clinical Experience with Trevena's Heart Failure Biased Ligand TRV027

Jul 08, 2013 7:00am EDT